It was reported yesterday that Denmark-based Novo Nordisk has agreed to pay USD58.65m to settle charges over the marketing of its type 2 diabetes drug Victoza (liraglutide) in the United States.
The settlement with the US federal government covers claims the company didn't comply with the USFDA's Risk Evaluation and Mitigation Strategy for the diabetes medication. An investigation into the charges was started in February 2011 regarding the sales and marketing practices of the Novo Nordisk diabetes drug.
Novo Nordisk will compensate around USD46.5m to the US government and to states that reimbursed for the medication under the Medicaid programme, along with USD12.15m to resolve a complaint filed by the government on FDA's behalf.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes